Pre-therapy Initial Dosimetry Results of Lu-177-DOTA-617-PSMA In Castration Resistant Prostate Cancer

被引：0
|
作者：
Abuqbeitah, M. M. [1 ]
Yeyin, N. [1 ]
Aygun, A. [1 ]
Demirci, E. [1 ]
Ocak, M. [1 ]
Demir, M. [1 ]
Kabasakal, L. [1 ]
机构：
[1] Istanbul Univ, Istanbul, Turkey
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P862
引用
收藏
页码：S752 / S752
页数：1
相关论文
共 50 条
  • [21] 44Sc and 177Lu labeling of DOTA-PSMA DKFZ-617 for dosimetry and therapy of prostate cancer
    Eppard, E.
    de La Fuente, A.
    Kuerpig, S.
    Roesch, F.
    Essler, M.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56
  • [22] Correlation between pre-therapy PSMA heterogeneity and treatment outcomes after Lu-177 PSMA (Pluvicto) in patients with metastatic castration-resistant prostate cancer
    Cardenas, Karol
    Atcheson, Kyle
    Bradley, Yong
    Benayoun, Marc
    Cengiz, Turgut Bora
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [23] 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sanli, Yasemin
    Simsek, Duygu Has
    Sanli, Oner
    Subramaniam, Rathan M.
    Kendi, Ayse Tuba
    BIOMEDICINES, 2021, 9 (04)
  • [24] Castration-resistant prostate cancer: [177Lu]Lu-PSMA-617 versus cabazitaxel Comment
    Todenhoefer, Tilman
    AKTUELLE UROLOGIE, 2023, 54 (04)
  • [25] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Houede, Nadine
    Hebert, Kevin
    LANCET ONCOLOGY, 2024, 25 (05): : 531 - 533
  • [26] 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
    Fadi Khreish
    Niklas Ebert
    Martin Ries
    Stephan Maus
    Florian Rosar
    Hendrik Bohnenberger
    Tobias Stemler
    Matthias Saar
    Mark Bartholomä
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 721 - 728
  • [27] 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
    Khreish, Fadi
    Ebert, Niklas
    Ries, Martin
    Maus, Stephan
    Rosar, Florian
    Bohnenberger, Hendrik
    Stemler, Tobias
    Saar, Matthias
    Bartholomae, Mark
    Ezziddin, Samer
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (03) : 721 - 728
  • [28] Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study.
    Herrmann, Ken
    Rahbar, Kambiz
    Eiber, Matthias
    Krause, Bernd J.
    Lassmann, Michael
    Jentzen, Walter
    Blumenstein, Lars
    Klein, Patrick
    Basque, Jean-Rene
    Kurth, Jens
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [29] PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
    Kratochwil, Clemens
    Giesel, Frederik L.
    Stefanova, Melsa
    Benesova, Martina
    Bronzel, Marcus
    Afshar-Oromieh, Ali
    Mier, Walter
    Eder, Matthias
    Kopka, Klaus
    Haberkorn, Uwe
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (08) : 1170 - 1176
  • [30] Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer
    Rahbar, Kambiz
    Bode, Axel
    Weckesser, Matthias
    Avramovic, Nemanja
    Claesener, Michael
    Stegger, Lars
    Boegemann, Martin
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (07) : 522 - 528
12345